Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure.
Open Access
- 22 May 2001
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 103 (20), 2441-2446
- https://doi.org/10.1161/01.cir.103.20.2441
Abstract
Background —Use of β-adrenoreceptor blockade in the treatment of heart failure has been associated with a reduction in myocardial oxygen consumption and an improvement in myocardial energy efficiency. One potential mechanism for this beneficial effect is a shift in myocardial substrate use from increased free fatty acid (FFA) oxidation to increased glucose oxidation. Methods and Results —We studied the effect of carvedilol therapy on myocardial FFA and glucose use in 9 patients with stable New York Heart Association functional class III ischemic cardiomyopathy (left ventricular ejection fraction ≤35%) using myocardial positron emission tomography studies and resting echocardiograms before and 3 months after carvedilol treatment. Myocardial uptake of the novel long chain fatty acid metabolic tracer 14(R, S)-[ 18 F]fluoro-6-thia-heptadecanoic acid ([ 18 F]-FTHA) was used to determine myocardial FFA use, and [ 18 F]fluoro-2-deoxy-glucose ([ 18 F]-FDG) was used to determine myocardial glucose use. After carvedilol treatment, the mean myocardial uptake rate for [ 18 F]-FTHA decreased (from 20.4±8.6 to 9.7±2.3 mL · 100 g –1 · min –1 ; P –1 · min –1 ; P 18 F]-FDG was unchanged (from 1.4±0.4 to 2.4±0.8 mL · 100 g –1 · min –1 ; P =0.14), and mean glucose use was unchanged (from 11.1±3.1 to 18.7±6.0 μmoL · 100 g –1 · min –1 ; P =0.12). Serum FFA and glucose concentrations were unchanged, and mean left ventricular ejection fraction improved (from 26±2% to 37±4%; P Conclusions —Carvedilol treatment in patients with heart failure results in a 57% decrease in myocardial FFA use without a significant change in glucose use. These metabolic changes could contribute to the observed improvements in energy efficiency seen in patients with heart failure.This publication has 23 references indexed in Scilit:
- Familial intracranial aneurysmsThe Lancet, 1997
- Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions Potential for pharmacological interventionsCardiovascular Research, 1997
- Improving the yield of 2- [18F]fluoro-2-deoxyglucose using a microwave cavityNuclear Medicine and Biology, 1996
- Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. GeneralizationsJournal of Cerebral Blood Flow & Metabolism, 1985
- Influence of free fatty acids on myocardial oxygen consumption and ischemic injuryThe American Journal of Cardiology, 1981
- Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischaemic rat heartLife Sciences, 1980
- Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: Comparison with a radioenzymatic methodLife Sciences, 1979
- Plasma norepinephrine in congestive heart failureThe American Journal of Cardiology, 1978
- Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heartJCI Insight, 1972
- Defective lipid metabolism in the failing heartJCI Insight, 1968